Xilio Therapeutics Begins XTX501 Clinical Trial
The company has dosed the first patient in a Phase 1/2 study evaluating a new bispecific antibody for lung cancer.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe biotechnology companies should receive support for developing proprietary, masked immuno-oncology therapies?
Xilio Therapeutics has initiated a first-in-human, open-label Phase 1/2 clinical trial for its drug candidate XTX501. The study focuses on patients with metastatic non-small cell lung cancer who have previously received anti-PD(L)-1 therapy.
Why it matters
XTX501 is designed to combine PD-1 inhibition with tumor-selective IL-2 activation to trigger immune responses while limiting the systemic toxicity often seen with non-masked IL-2 therapies.
The clinical trial for XTX501, which is a PD-1/masked IL-2 bispecific antibody fusion protein, is registered under NCT07688577. This multi-center study is currently evaluating the safety and tolerability of the drug as a monotherapy in oncology patients.
The players
Xilio Therapeutics
A clinical-stage biotechnology company based in Waltham, Massachusetts, that focuses on developing tumor-selective therapies.
The details
The trial utilizes a design intended to deliver tumor-selective immune activation. Researchers are specifically examining how the masking technology functions to minimize toxicities associated with traditional immune-stimulating IL-2 agents.
Timeline
The first patient was dosed on October 26, 2026.
The SITC 41st Annual Meeting takes place from November 4-8, 2026.
A trial-in-progress poster is scheduled for presentation on November 7, 2026.
Initial Phase 1 trial data is expected in the fourth quarter of 2027.
The Tech Race
This development follows the industry push to move beyond standard PD-1 inhibition by engineering bispecific proteins that offer more precise control over immune system activation. It represents a shift toward masked, tumor-selective molecules that aim to outperform earlier cytokine-based therapies.
This trial offers a potential new treatment pathway for patients with metastatic non-small cell lung cancer who have exhausted initial anti-PD(L)-1 options. While still in early stages, the technology aims to improve quality of life by reducing the severe toxicities that often limit the use of standard systemic immune therapies.
The takeaway
The study marks a shift toward more targeted immune-modulating cancer treatments that prioritize reduced patient toxicity. Continued monitoring of clinical progress will clarify whether the masked bispecific approach can effectively enhance therapeutic efficacy.
What happens next
Xilio Therapeutics will present a trial-in-progress poster, labeled as abstract 542, at the SITC 41st Annual Meeting on November 7, 2026. The company also anticipates reporting initial Phase 1 data in the fourth quarter of 2027.
Further reading
For more developments in new medical therapies, visit the Biotech section.
More information
To search for details on this study, visit the clinical trials government search portal.
Live Poll
Do you believe biotechnology companies should receive support for developing proprietary, masked immuno-oncology therapies?
